The impact of device-assisted therapies on the gut microbiome in Parkinson’s disease
- 15 June 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Zeitschrift für Neurologie
- Vol. 269 (2), 780-795
- https://doi.org/10.1007/s00415-021-10657-9
Abstract
Background Microbiome feedbacks are proposed to influence Parkinson’s disease (PD) pathophysiology. A number of studies have evaluated the impact of oral medication on the gut microbiome (GM) in PD. However, the influence of PD device-assisted therapies (DATs) on the GM remains to be investigated. Objectives To profile acute gut microbial community alterations in response to PD DAT initiation. Methods Clinical data and stool samples were collected from 21 PD patients initiating either deep brain stimulation (DBS) or levodopa–carbidopa intestinal gel (LCIG) and ten spousal healthy control (HC) subjects. 16S amplicon sequencing of stool DNA enabled comparison of temporal GM stability between groups and with clinical measures, including disease alterations relative to therapy initiation. Results We assessed GM response to therapy in the PD group by comparing pre-therapy (− 2 and 0 weeks) with post-therapy initiation timepoints (+ 2 and + 4 weeks) and HCs at baseline (0 weeks). Altered GM compositions were noted between the PD and HC groups at various taxonomic levels, including specific differences for DBS (overrepresentation of Clostridium_XlVa, Bilophila, Parabacteroides, Pseudoflavonifractor and underrepresentation of Dorea) and LCIG therapy (overrepresentation of Pseudoflavonifractor, Escherichia/Shigella, and underrepresentation of Gemmiger). Beta diversity changes were also found over the 4 week post-treatment initiation period. Conclusions We report on initial short-term GM changes in response to the initiation of PD DATs. Prior to the introduction of the DAT, a PD-associated GM was observed. Following initiation of DAT, several DAT-specific changes in GM composition were identified, suggesting DATs can influence the GM in PD.Keywords
Funding Information
- Parkinson's New South Wales (Research Seed Grant)
This publication has 63 references indexed in Scilit:
- Gut microbiota disturbance during antibiotic therapy: a multi-omic approachGut, 2012
- Evaluation of general 16S ribosomal RNA gene PCR primers for classical and next-generation sequencing-based diversity studiesNucleic Acids Research, 2012
- Systematic review of levodopa dose equivalency reporting in Parkinson's diseaseMovement Disorders, 2010
- Validity of carbohydrate, glycaemic index and glycaemic load data obtained using a semi-quantitative food-frequency questionnairePublic Health Nutrition, 2008
- Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Process, format, and clinimetric testing planMovement Disorders, 2007
- Akkermansia muciniphila gen. nov., sp. nov., a human intestinal mucin-degrading bacteriumInternational Journal of Systematic and Evolutionary Microbiology, 2004
- The Leeds Dyspepsia Questionnaire: a valid tool for measuring the presence and severity of dyspepsiaAlimentary Pharmacology & Therapeutics, 1998
- Stool Form Scale as a Useful Guide to Intestinal Transit TimeScandinavian Journal of Gastroenterology, 1997
- The MOS 36-ltem Short-Form Health Survey (SF-36)Medical Care, 1992
- Clinical applications of visual analogue scales: a critical reviewPsychological Medicine, 1988